Wells Fargo lowered the firm’s price target on Axsome Therapeutics (AXSM) to $157 from $163 and keeps an Overweight rating on the shares. The firm believes AXS-05 approval in Alzheimer’s disease agitation offers upside to shares, as it continues to see regulatory approval as the most likely outcome. Wells thinks stock volatility is possible near-term as investors scrutinize priority vs. standard; its base case is standard given Rexulti.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics Reports Strong Q3 2025 Growth
- Axsome Therapeutics’ Strong Market Position and Growth Potential Highlighted by Impressive Auvelity Performance and Strategic Expansion
- Axsome Therapeutics files automatic mixed securities shelf
- Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy Rating
- Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Justify Buy Rating